Your blood will be sent to a laboratory for analysis. If the lab analysis is done on-site, you could have your test results within hours. If your doctor sends your blood to an off-site laboratory, you may receive the results within several days. These results are typical for adult men. Normal results vary from laboratory to laboratory and might be slightly different for women and children. Your doctor will use these results to help diagnose your condition or determine treatment you might need.
If you already have liver disease, liver function tests can help determine how your disease is progressing and if you're responding to treatment. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
This content does not have an English version. This content does not have an Arabic version. Overview Liver function tests are blood tests used to help diagnose and monitor liver disease or damage. Request an Appointment at Mayo Clinic. Share on: Facebook Twitter. Show references Diagnosing liver disease: Liver biopsy and liver function tests.
Damage to the bile ducts is a rare complication that should also watched for. If you're taking the following medications for liver disease, you may be wondering how your treatment could be affected by the pandemic in general, as well as if you contract COVID For people with liver disease who develop COVID, there are now a number of recommendations for treatment. Because the infection may lead to liver decompensation, liver function tests ALT and AST should be monitored regularly, especially if medications that have potential liver toxicity are also being used.
Since COVID can lead to abnormal liver function tests, however, it's important for doctors and patients not to immediately assume the abnormality is due to worsening liver disease. For example, if someone has had a liver transplant and has an increase in liver enzymes, a biopsy removal of a small tissue sample to be tested should be done to see if it is rejection vs.
It's important to keep in mind that these are general recommendations meant to cover a wide variety of people with differing liver dysfunction. For that reason, your doctor may make recommendations for you that are different. Note: There are a number of drug interactions between medications used for some liver diseases and antivirals used for COVID Using these drugs will need to be carefully evaluated by your healthcare team.
If a liver transplant patient develops COVID, withdrawal or reduction of immunosuppressive medications may not be needed. But if reducing meds is necessary, the outcome can still be positive. A multicenter study looking at people with liver transplants found that, even when immunosuppression was reduced during COVID, it did not appear to increase the risk of either organ failure or mortality. Treatments for liver disease should mostly be continued throughout the pandemic unless otherwise directed by your healthcare provider.
If you do contract COVID, your healthcare provider will advise you on the best course of treatment. This may include whether to reduce or stop certain treatments like corticosteroids or immunosuppressant medications, to improve your prognosis. Liver disease can increase your susceptibility to COVID infection and raise the overall risk of severe illness should you become infected.
As such, it's important to follow public health recommendations such as social distancing, wearing a mask in public, and washing hands often to protect yourself. Your healthcare provider can advise you on any additional precautions you should take for your specific circumstances, such as changes to certain medications that suppress the immune system.
Living with liver disease during the pandemic can be anxiety provoking due to the increased risk of serious disease. Diagnosing COVID early, however, can be challenging, especially as typical symptoms may be absent or may resemble those of a liver flare.
Being your own advocate, speaking up, and asking questions can help ensure you get the best care possible while the pandemic continues. People with liver disease are often accustomed to having some symptoms that may mimic symptoms of COVID What's more, one study found that You should be tested if you experience:.
Due to the increased risk of severe disease with COVID in people who have liver disease, vaccination is not only recommended, but considered a top priority. The vaccine does not mean that therapy needs to be delayed with medications for chronic hepatitis or autoimmune liver disease.
For those who are candidates for liver transplantation, vaccination should be done as soon as possible to help ensure a good immune response prior to the transplant. It's recommended that people who are a candidate for transplantation, as well as their household contacts, complete the vaccine series at least two weeks prior to transplantation.
The information in this article is current as of the date listed. Sign up for our Health Tip of the Day newsletter, and receive daily tips that will help you live your healthiest life. Clinical outcomes in COVID and cirrhosis: a systematic review and meta-analysis of observational studies.
BMJ Open Gastroenterol. J Hepatol. SN Compr Clin Med. Risk prediction models for post-operative mortality in patients with cirrhosis. J Med Virol. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID A comprehensive systematic review and meta-analysis of 77 studies and 38, patients.
PLoS One. Predictors of in-hospital COVID mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. Liver disease and coronavirus disease from pathogenesis to clinical care.
Ann Hepatol. World J Gastroenterol. Clin Gastroenterol Hepatol. Nat Med. Martinez MA, Franco S. Hepatol Commun. Gastroenterol Hepatol. Second, after being trapped in the sinusoids, how do effector T cells mediate liver damage in the absence of their cognate antigen? One mechanism could be local ischemic necrosis precipitated by trapping of lymphocytes in the sinusoids and the consequent disturbance in blood flow.
However, the nature of the lesions in the present study is against such a simple mechanism. The foci are organized into multicellular aggregates associated with hepatocyte apoptosis, suggesting that after trapping, the T cells migrate across the sinusoids to interact with underlying hepatocytes. However, this seems unlikely given the fact that a similar hepatitis was seen when effector cells were expanded in response to two serologically distinct influenza viruses and to the model OVA peptide antigen SIINFEKL.
Furthermore, the fact that resolution of the hepatitis paralleled resolution of the anti-viral response in the lung would argue against a classical autoimmune mechanism. It seems more likely that the recruitment of activated effector cells to the liver parenchyma results in direct activation of effector pathways by mechanisms similar to the bystander effect seen in other infections.
Kupffer cells were required for the development of the lymphocytic foci but not for the recruitment of virus-specific cells to the liver. It is not clear how Kupffer cells promote hepatitis.
Kupffer cells can kill hepatocytes directly via activation of Fas-dependent pathways, thereby contributing directly to local tissue damage, 15 and interactions between Kupffer cells and infiltrating T cells can stimulate cytokine secretion, thereby promoting inflammation. Third, the study has potentially important clinical implications for liver involvement in systemic viral infections.
By contrast in the collateral damage model proposed by Polakos et al, 6 there is a pathological process leading to tissue damage.
Further evidence that collateral damage in response to influenza virus may be clinically significant comes from recent reports that influenza infection can lead to exacerbation of chronic liver disease and can act as a trigger for liver allograft rejection. In these cases, although SARS-associated coronavirus was detected in the liver tissues by reverse transcriptase-polymerase chain reaction, no viral particles were seen at electron microscopy. Alternatively, both mechanisms could operate in tandem to amplify liver damage.
Finally, the collateral damage model proposed by Polakos et al 6 in this issue of The American Journal of Pathology may be involved in other poorly understood forms of hepatitis. Searches for hepatic viruses in the latter condition have not been fruitful, and it is possible that liver damage here is also driven by collateral damage related to an extrahepatic viral infection triggering a rapid expansion of activated T cells.
Address reprint requests to David H. This commentary relates to Polakos et al, Am J Pathol , —, published in this issue. National Center for Biotechnology Information , U. Journal List Am J Pathol v. Am J Pathol. David H. Adams and Stefan G. Author information Article notes Copyright and License information Disclaimer. Accepted Jan This article has been cited by other articles in PMC. Understanding Hepatitis in Influenza It is known that severe influenza infection can be associated with abnormalities in liver biochemistry that resolve after successful clearance of the virus, 7 but the current study is the first to look systematically for liver involvement in volunteers infected with influenza virus.